Additionally, similar to a previous report that silencing of β-catenin expression with siRNA inhibited drug resistance in A549 NSCLC [32], our present study showed a strong inhibitory action in nuclear β-catenin-dependent TCF/LEF1 transcriptional activity by SMA, also suggesting that SMA may be applied for cisplatin-resistant lung cancer. This evidence concerns the gene SMN1 and non-small cell lung carcinoma.